NMS1286937 is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. NMS-1286937 selectively and effectively inhibits PLK1 (with IC50 at low nM), inducing selective G2/M cell-cycle arrest followed by apoptosis in a variety of tumor cells while causing reversible cell-cycle arrest at the G1 and G2 stages without apoptosis in normal cells.

KEYWORDS: NMS-1286937 | Supplier | PLK1 inhibitor | Onvansertib | NMS-P 937 | NMS1286937 | NMS 1286937 | NMS-P-937 | NMS-P-937 | CT-NMS128 | CAS [1034616-18-6] | Non Selective (CHK2;p53) | PLK | Inhibitor | Enzymes